Back

NFL-101 report forecasts smoking-cessation sales through 2034

Verifying
  • NFL Biosciences is advancing NFL-101, a botanical drug candidate for smoking cessation.
  • Phase II CESTO II reported 24.1% abstinence with NFL-101 versus 12.9% with placebo.
  • The report forecasts NFL-101 sales through 2034 across seven major pharmaceutical markets.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.